MEMORANDUM

TO:		Public Record for the NPDES Electronic Reporting Rule
		EPA Docket Number EPA-HQ-OECA-2009-0274 (www.regulations.gov)

FROM:	Carey A. Johnston, P.E.
            USEPA/OECA/OC

DATE:		11 March 2011

--------------------------------------------------------------------------------
SUBJECT: 	Meeting Notes from Meeting with IRS on Working with Third-party Commercial Software Providers [DCN 0041]
--------------------------------------------------------------------------------

I. 	Introduction

      EPA announced on July 6, 2009, that it would develop a Clean Water Action Plan to enhance public transparency regarding clean water enforcement performance at federal and state levels, to strengthen that performance, and to transform EPA's water quality and compliance information systems. A consensus suggestion across co-regulators and stakeholder groups was to implement electronic reporting from facilities that are required to submit reports to a regulatory agency. To fully realize the transformation of reporting and data management into the 21st Century, OECA is developing a rule to require NPDES permittees to provide a variety of environmental information electronically.

      EPA is exploring different electronic reporting options to enable NPDES regulated facilities to electronically submit their compliance monitoring data. EPA is exploring the option of electronic reporting of NPDES compliance monitoring data from regulated facilities via an `open platform e-file' electronic reporting. The `open platform e-file' proof of concept demonstration will focus the electronic transmission of NPDES (DMRs from a third-party commercial software provider to EPA. If EPA were to fully implement this option, any commercial software provider that meets the Agency's data exchange standards, protocols, and specifications would be able to offer electronic reporting services to the regulated community for the NPDES program (e.g., NPDES permitted facilities). This open platform model would likely be similar to the Internal Revenue Service (IRS) model for electronic reporting, which uses third-party software providers for tax data collection and transmission (e.g., TurboTax, TaxACT) from private citizens and businesses.

      EPA held a teleconference with technical staff from the IRS to better understand some of the potential requirements on EPA and third-party commercial software providers for the open platform e-file option. This memorandum provides the meeting notes of this teleconference. Attachment A provides the list of participants and questions for teleconference.

II. 	Meeting Notes

The IRS started Modernized e-File (MeF) in 2004 and the IRS is incorporating more forms each year into MeF. The benefits to the user are faster processing and detailed error messages (if there are problems with data submissions).

The IRS uses Simple Object Access Protocol (SOAP), Extensible Markup Language (XML), and web services to facilitate data transfers with third-party commercial software providers.

In order to pass data to the IRS commercial software providers must be suitable (e.g., must not have a criminal history). After they pass this check they must prove their competency with data exchange services by pass a test administered by the IRS.

The IRS test involves sample data that vendors must show that they can correctly code and transmit tax data to the IRS. The IRS publishes the XML schema and business rules and vendors must show that they can comply with both.

The competency test usually lasts 40 to 60 days and will involve IRS staff to help decode error log messages. Mr. Ostro noted that a few occasion vendors have failed the competency test and that he has had to turn them away from participation in MeF until they gain the necessary experience.

Mr. Ostro noted that software providers will be a partner in any e-File option as they sit between the Federal agency and the data provider. The Federal agency needs to have a good relationship with the software providers and there needs to be good communication between both parties. This includes a good error response system so that software providers can de-bug their software. This also includes good documentation explaining how to implement web services and XML for MeF.

Mr. Ostro noted that they have a number of ways in which the IRS communicates with software providers. They use a website, conferences, workshops, and e-mail newsletters to share the latest developments with MeF.

Mr. Ostro noted that in dealing with third-party commercial software providers there is a need to purchase XML firewalls to defend against security threats (e.g., SQL injection attacks)

Mr. Ostro estimates that there are between 50 and 100 third-party commercial software providers for the IRS 1040 Form, which is one of their most popular forms. Other less popular forms (U.S. Corporation Income Tax Return  -  Form 1120) have approximately a dozen third-party commercial software providers.

Mr. Ostro noted that states also share their schemas with the IRS as many state tax forms filed by taxpayers first go to the IRS and are then re-routed to state data systems.

        Attachment A: List of Participants and Questions for Teleconference
                              EPA/IRS Teleconference
                                 18 February 2011
                                     Name
                                 Organization
                                 Phone Number
                                     Email
                                Carey Johnston
                              EPA Office of Water
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                John Dombrowski
                           EPA Office of Compliance
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                   Lucy Reed
                           EPA Office of Compliance
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                Rochele Kadish
                           EPA Office of Compliance
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                 Alison Kittle
                           EPA Office of Compliance
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                  Roy Chaudet
                    EPA Office of Environmental Information
<PHONE_NUMBER>
<EMAIL_ADDRESS>                               Tobias Schroeder
                    EPA Office of Environmental Information
<PHONE_NUMBER>
<EMAIL_ADDRESS>                                   Xan Ostro
                           Internal Revenue Service
<PHONE_NUMBER>
<EMAIL_ADDRESS>
List of Questions for Teleconference
What mechanism(s) do you use to generate interest among vendors for participating in the IRS's electronic reporting system?
How do you ensure open competition among vendors?
How do you vet potential third-party software vendors when considering their potential for tying into the IRS electronic reporting system? What criteria did you use to evaluate whether the interested vendors were qualified to meet the goals of the project?
How do you communicate with the vendors (e.g., individually, as a group, web - http://www.irs.gov/taxpros/providers/article/0,,id=101145,00.html )?
What number of IRS FTE and other resources are dedicated to working with third-party software vendors to ensure proper communication?
If a vendor required considerable more hand holding than others, how do you handle this situation (e.g., gave them what they needed, disqualified them as eligible)?
What criteria do you use for testing and how many failures do you allow before disqualification of a third-party software vendor?
What is the time frame for bringing a new vendor into the IRS's electronic reporting system?
What is the approximately number and type of vendors that provide electronic reporting services to tax filers?
What is the number of electronic tax submissions each year and the amount of data exchanged?
Is the following document the best resources to get an overall big picture on how the IRS works with third-party software vendors?
Modernized e-File (MeF) Guide for Software Developers And Transmitters (Publication 4164, Revision 10/2010)


[Federal Register: April 25, 2008 (Volume 73, Number 81)]
[Rules and Regulations]
[Page 22277]
[DOCID:fr25ap08-3]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[Docket No. USCG-2008-0001]

Drawbridge Operation Regulations; Chelsea River, Chelsea and East
Boston, MA

AGENCY: Coast Guard, DHS.

ACTION: Notice of temporary deviation from regulations.

-----------------------------------------------------------------------

SUMMARY: The Commander, First Coast Guard District, has issued a
temporary deviation from the regulation governing the operation of the
P.J. McArdle Bridge across the Chelsea River, mile 0.3, between Chelsea
and East Boston, Massachusetts. This deviation is necessary to
facilitate the annual Chelsea River Revel and 5K Road Race. This
deviation allows the bridge to remain in the closed position during the
running of the 5K Road Race. Vessels that can pass under the draw
without a bridge opening may do so at all times.

DATES: This deviation is effective from 8 a.m. through 5 p.m. on June
14, 2008.

ADDRESSES: Documents indicated in this preamble as being available in
the docket are part of docket USCG-2008-0001 and are available online
at www.regulations.gov. They are also available for inspection or
copying at two locations: The Docket Management Facility (M-30), U.S.
Department of Transportation, West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5
p.m., Monday through Friday, except Federal holidays, and the First
Coast Guard District, Bridge Branch Office, 408 Atlantic Avenue,
Boston, Massachusetts 02110, between 7 a.m. and 3 p.m., Monday through
Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: John McDonald, Project Officer, First
Coast Guard District, at<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The owner of the bridge, the City of Boston,
requested this temporary deviation. The P.J. McArdle Bridge, across the
Chelsea River at mile 0.3, between Chelsea and East Boston,
Massachusetts, has a vertical clearance in the closed position of 21
feet at mean high water and 30 feet at mean low water. The bridge opens
on signal as required by 33 CFR 117.593. This deviation which allows
the bridge to remain closed is effective from 8 a.m. through 5 p.m. on
June 14, 2008. Vessels able to pass under the closed draw may do so at
any time. Tankers, and tug and barge units transit Chelsea Creek under
the McArdle Bridge. Waterway users were advised of the requested bridge
closure period and offered no objection.
    In accordance with 33 CFR 117.35(e), the bridge must return to its
regular operating schedule immediately at the end of the designated
time period. This deviation from the operating regulations is
authorized under 33 CFR 117.35.

    Dated: April 17, 2008.
Gary Kassof,
Bridge Program Manager, First Coast Guard District.
 [FR Doc. E8-8993 Filed 4-24-08; 8:45 am]

BILLING CODE 4910-15-P


[Federal Register Volume 83, Number 18 (Friday, January 26, 2018)]
[Notices]
[Pages 3732-3734]
[FR Doc No: 2018-01373]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-E-2475]

Determination of Regulatory Review Period for Purposes of Patent
Extension; VARUBI

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) has
determined the regulatory review period for VARUBI and is publishing
this notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Director of the U.S. Patent and Trademark Office (USPTO), Department of
Commerce, for the extension of a patent which claims that human drug
product.

DATES: Anyone with knowledge that any of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are incorrect may submit either
electronic or written comments and ask for a redetermination by March
27, 2018. Furthermore, any interested person may petition FDA for a
determination regarding whether the applicant for extension acted with
due diligence during the regulatory review period by July 25, 2018. See
``Petitions'' in the SUPPLEMENTARY INFORMATION section for more
information.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before March 27, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of March 27, 2018. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:

     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2016-E-2475 for ''Determination of Regulatory Review Period for
Purposes of Patent Extension; VARUBI.'' Received comments, those filed
in a timely manner (see ADDRESSES), will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with Sec.  10.20 (21 CFR 10.20) and
other applicable disclosure law. For more information about FDA's
posting of comments to public dockets, see 80 FR 56469, September 18,
2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 6250, Silver Spring, MD 20993,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    The Drug Price Competition and Patent Term Restoration Act of 1984
(Pub. L. 98-417) and the Generic Animal Drug and Patent Term
Restoration Act (Pub. L. 100-670) generally provide that a patent may
be extended for a period of up to 5 years so long as the patented item
(human drug product, animal drug product, medical device, food
additive, or color additive) was subject to regulatory review by FDA
before the item was marketed. Under these acts, a product's regulatory
review period forms the basis for determining the amount of extension
an applicant may receive.
    A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of USPTO may award
(for example, half the testing phase must be subtracted as well as any
time that may have occurred before the patent was issued), FDA's
determination of the length of a regulatory review period for a human
drug product will include all of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
    FDA has approved for marketing the human drug product VARUBI
(rolapitant). VARUBI is indicated in combination with other antiemetic
agents in adults for the prevention of delayed nausea and vomiting
associated with initial and repeat courses of emetogenic cancer
chemotherapy, including, but not limited to, highly emetogenic
chemotherapy. Subsequent to this approval, the USPTO received a patent
term restoration application for VARUBI (U.S. Patent No. 7,049,320)
from OPKO Health, Inc., and the USPTO requested FDA's assistance in
determining this patent's eligibility for patent term restoration. In a
letter dated November 2, 2016, FDA advised the USPTO that this human
drug product had undergone a regulatory review period and that the
approval of VARUBI represented the first permitted commercial marketing
or use of the product. Thereafter, the USPTO requested that FDA
determine the product's regulatory review period.

II. Determination of Regulatory Review Period

    FDA has determined that the applicable regulatory review period for
VARUBI is 3,070 days. Of this time, 2,708 days occurred during the
testing phase of the regulatory review period, while 362 days occurred
during the approval phase. These periods of time were derived from the
following dates:
    1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(i)) became effective:
April 8, 2007. FDA has verified the applicant's claim that the date the
investigational new drug application became effective was on April 8,
2007.
    2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the FD&C Act: September
5, 2014. FDA has verified the applicant's claim that the new drug
application (NDA) for VARUBI (NDA 206500) was initially submitted on
September 5, 2014.
    3. The date the application was approved: September 1, 2015. FDA
has verified the applicant's claim that NDA 206500 was approved on
September 1, 2015.
    This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the USPTO
applies several statutory limitations in its calculations of the actual
period for patent extension. In its application for patent extension,
this applicant seeks 1,716 days of patent term extension.

III. Petitions

    Anyone with knowledge that any of the dates as published are
incorrect may submit either electronic or written comments and, under
21 CFR 60.24, ask for a redetermination (see DATES). Furthermore, as
specified in Sec.  60.30 (21 CFR 60.30), any interested person may
petition FDA for a determination regarding whether the applicant for
extension acted with due diligence during the regulatory review period.
To meet its burden, the petition must comply with all the requirements
of

Sec.  60.30, including but not limited to: Must be timely (see DATES),
must be filed in accordance with Sec.  10.20, must contain sufficient
facts to merit an FDA investigation, and must certify that a true and
complete copy of the petition has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42,
1984.) Petitions should be in the format specified in 21 CFR 10.30.
    Submit petitions electronically to https://www.regulations.gov at
Docket No. FDA-2013-S-0610. Submit written petitions (two copies are
required) to the Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

    Dated: January 19, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-01373 Filed 1-25-18; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 76, Number 229 (Tuesday, November 29, 2011)]
[Rules and Regulations]
[Pages 73506-73508]
[FR Doc No: 2011-30591]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

17 CFR Part 232

[Release Nos. 33-9281; 34-65803; 39-2481; IC-29868]

Adoption of Updated EDGAR Filer Manual

AGENCY: Securities and Exchange Commission.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Securities and Exchange Commission (the Commission) is
adopting revisions to the Electronic Data Gathering, Analysis, and
Retrieval System (EDGAR) Filer Manual to reflect updates to the EDGAR
system. The revisions are being made primarily to support the updates
to submission form types ABS-15G and ABS-15G/A; to support changes in
XBRL validations for filings containing Exhibit 101 documents; to
update the OMB information on EDGARLite Form TA-W; and to add a new
applicant type to the Form ID. The EDGAR system is scheduled to be
upgraded to support this functionality on November 21, 2011.
    The filer manual is also being revised to address changes
previously made in EDGAR.

DATES: Effective Date: November 29, 2011. The incorporation by
reference of the EDGAR Filer Manual is approved by the Director of the
Federal Register as of November 29, 2011.

FOR FURTHER INFORMATION CONTACT: In the Division of Corporation
Finance, for questions concerning submission form types ABS-15G and
ABS-15G/A contact Heather Mackintosh, Office of Information Technology,
at<PHONE_NUMBER>; in the Division of Trading and Markets for questions
regarding new Form ID applicant type and OMB expiration date for Forms
TA-W contact Catherine Moore, Special Counsel, Office of Clearance and
Settlement, at<PHONE_NUMBER>; in the Division of Risk, Strategy, and
Financial Innovation for questions concerning XBRL validation
requirements contact Walter Hamscher, at<PHONE_NUMBER>; and in the
Office of Information Technology, contact Rick Heroux, at (202) 551-
8800.

SUPPLEMENTARY INFORMATION: We are adopting an updated EDGAR Filer
Manual, Volume I and Volume II. The Filer Manual describes the
technical formatting requirements for the preparation and submission of
electronic filings through the EDGAR

system.\1\ It also describes the requirements for filing using
EDGARLink Online and the Online Forms/XML Web site.
---------------------------------------------------------------------------

    \1\ We originally adopted the Filer Manual on April 1, 1993,
with an effective date of April 26, 1993. Release No. 33-6986 (April
1, 1993) [58 FR 18638]. We implemented the most recent update to the
Filer Manual on August 5, 2011. See Release No. 33-9246 (August 1,
2011) [76 FR 47438].
---------------------------------------------------------------------------

    The revisions to the Filer Manual reflect changes within Volume I
entitled EDGAR Filer Manual, Volume I: ``General Information,'' Version
11 (November 2011) and Volume II entitled EDGAR Filer Manual, Volume
II: ``EDGAR Filing,'' Version 18 (November 2011). The updated manual
will be incorporated by reference into the Code of Federal Regulations.
    The Filer Manual contains all the technical specifications for
filers to submit filings using the EDGAR system. Filers must comply
with the applicable provisions of the Filer Manual in order to assure
the timely acceptance and processing of filings made in electronic
format.\2\ Filers may consult the Filer Manual in conjunction with our
rules governing mandated electronic filing when preparing documents for
electronic submission.\3\
---------------------------------------------------------------------------

    \2\ See Rule 301 of Regulation S-T (17 CFR 232.301).
    \3\ See Release No. 33-9246 (August 1, 2011) [76 FR 47438] in
which we implemented EDGAR Release 11.2. For additional history of
Filer Manual rules, please see the cites therein.
---------------------------------------------------------------------------

    The EDGAR system will be upgraded to Release 11.3 on November 21,
2011 and will introduce the following changes: EDGAR will be upgraded
to support updates to submission form type ABS-15G and ABS-15G/A based
upon final Rule 15Ga-1.\4\ ABS-15G Item 1.02 will require start and end
date of reporting period and also a file number if the securitizer has
previously filed an ABS-15G under Item 1.01 for the same Asset Class as
the report. ABS-15G Item 1.02 will have an option to indicate if the
securitizer has no activity to report for the quarterly period pursuant
to Rule 15Ga-1(c)(2)(i) and/or for the annual period pursuant to Rule
15Ga-1(c)(2)(ii). ABS-15G Item 1.01 will have an option to indicate
that the securitizer has no activity to report for the initial period
pursuant to Rule 15Ga-1(c)(1). Additionally, EDGAR will allow
submission of multiple ABS-15G Item 1.01 submissions per CIK.
---------------------------------------------------------------------------

    \4\ See Final Rule Release No. 33-9175, Disclosure for Asset-
Backed Securities Required by Section 943 of the Dodd-Frank Wall
Street Reform and Consumer Protection Act.
---------------------------------------------------------------------------

    The validation rules processed for filings containing EX-101.INS
XBRL documents will be changed to require all elements used to have US
English standard labels and all non-English non-empty facts to have
corresponding US English variants.
    Submission form types 10-KT, 10-KT/A, 10-QT, 10-QT/A and POS AM can
now be filed with XBRL documents. EX-101.INS XBRL documents included
within POS AM submissions can have the element dei:DocumentType with
content equal to F-1, F-3, F-4, F-9, F-10, S-1, S-3, S-4, S-11, POS AM
or ``Other''.
    The OMB expiration date on EDGARLite Form TA-W (Notice of
Withdrawal from Registration as Transfer Agent) will be updated to July
31, 2014.
    New applicant type `Municipal Advisor' will be available for the
filers to select when completing the Form ID to apply for EDGAR access
codes. In addition, applicant types `Investment Company (or insurance
product separate account) or Business Development Company' and `Non-
Investment Company Applicant under the 1940 Act' will be updated to
`Investment Company, Business Development Company or Insurance Company
Separate Account' and `Non-Investment Company Applicant under the
Investment Company Act of 1940' respectively.
    There will be a minor .dot release, EDGAR Release 11.3.1, that will
be deployed after Release 11.3 to implement additional XBRL validation
changes. On December 12, 2011, the validation rules processed for
filings containing EX-101.INS XBRL documents will be changed to require
four digit xs:gYear values and will allow distinct values for all
outstanding common share classes instead of requiring a single value
for dei:EntityCommonStockSharesOutstanding of annual financial
statements. For EX-101.SCH documents, the xsd:complexType, or
xsd:simpleType name attribute in UTF-8 must be less than 200 bytes of
UTF-8 text. The content for targetnamespace, roleURI or arcroleURI
attribute in UTF-8 must not exceed 255 bytes in length. For EX-101.INS
documents, the local name part of the content for xbrli:measure:element
must be less than 200 bytes of text.
    The filer manual is also being revised to address minor software
changes made previously in EDGAR. Submission form types SC 14N, SC 14N-
S and their amendments were made available for use on EDGARLink Online.
Form 8-K Item 5.08 (Shareholder Director Nominations) was also made
available for use on submission form types 8-K, 8-K12B, 8-K12G3, 8-
K15D5 and their amendments.
    Submission form types 13F-HR, 13F-HR/A, 13F-NT and 13F-NT/A were
updated to accept March 31, June 30, September 30, or December 31 as
valid dates for the Period field. A future date will still be not
allowed for the Period field.
    Along with the adoption of the Filer Manual, we are amending Rule
301 of Regulation S-T to provide for the incorporation by reference
into the Code of Federal Regulations of today's revisions. This
incorporation by reference was approved by the Director of the Federal
Register in accordance with 5 U.S.C. 552(a) and 1 CFR Part 51.
    You may obtain paper copies of the updated Filer Manual at the
following address: Public Reference Room, U.S. Securities and Exchange
Commission, 100 F Street NE., Room 1543, Washington, DC 20549, on
official business days between the hours of 10 a.m. and 3 p.m. We will
post electronic format copies on the Commission's Web site; the address
for the Filer Manual is http://www.sec.gov/info/edgar.shtml.
    Since the Filer Manual relates solely to agency procedures or
practice, publication for notice and comment is not required under the
Administrative Procedure Act (APA).\5\ It follows that the requirements
of the Regulatory Flexibility Act \6\ do not apply.
---------------------------------------------------------------------------

    \5\ 5 U.S.C. 553(b).
    \6\ 5 U.S.C. 601-612.
---------------------------------------------------------------------------

    The effective date for the updated Filer Manual and the rule
amendments is November 29, 2011. In accordance with the APA,\7\ we find
that there is good cause to establish an effective date less than 30
days after publication of these rules. The EDGAR system upgrade to
Release 11.3 is scheduled to become available on November 21, 2011. The
Commission believes that establishing an effective date less than 30
days after publication of these rules is necessary to coordinate the
effectiveness of the updated Filer Manual with the system upgrade.
---------------------------------------------------------------------------

    \7\ 5 U.S.C. 553(d)(3).
---------------------------------------------------------------------------

Statutory Basis

    We are adopting the amendments to Regulation S-T under Sections 6,
7, 8, 10, and 19(a) of the Securities Act of 1933,\8\ Sections 3, 12,
13, 14, 15, 23, and 35A of the Securities Exchange Act of 1934,\9\
Section 319 of the Trust Indenture Act of 1939,\10\ and Sections 8, 30,
31, and 38 of the Investment Company Act of 1940.\11\
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 77f, 77g, 77h, 77j, and 77s(a).
    \9\ 15 U.S.C. 78c, 78l, 78m, 78n, 78o, 78w, and 78ll.
    \10\ 15 U.S.C. 77sss.
    \11\ 15 U.S.C. 80a-8, 80a-29, 80a-30, and 80a-37.

---------------------------------------------------------------------------

List of Subjects in 17 CFR Part 232

    Incorporation by reference, Reporting and recordkeeping
requirements, Securities.

Text of the Amendment

    In accordance with the foregoing, Title 17, Chapter II of the Code
of Federal Regulations is amended as follows:

PART 232--REGULATION S-T--GENERAL RULES AND REGULATIONS FOR
ELECTRONIC FILINGS

0
1. The authority citation for Part 232 continues to read in part as
follows:

    Authority: 15 U.S.C. 77f, 77g, 77h, 77j, 77s(a), 77z-3,
77sss(a), 78c(b), 78l, 78m, 78n, 78o(d), 78w(a), 78ll, 80a-6(c),
80a-8, 80a-29, 80a-30, 80a-37, and 7201 et seq.; and 18 U.S.C. 1350.
* * * * *

0
2. Section 232.301 is revised to read as follows:

Sec.  232.301  EDGAR Filer Manual.

    Filers must prepare electronic filings in the manner prescribed by
the EDGAR Filer Manual, promulgated by the Commission, which sets out
the technical formatting requirements for electronic submissions. The
requirements for becoming an EDGAR Filer and updating company data are
set forth in the updated EDGAR Filer Manual, Volume I: ``General
Information,'' Version 11 (November 2011). The requirements for filing
on EDGAR are set forth in the updated EDGAR Filer Manual, Volume II:
``EDGAR Filing,'' Version 18 (November 2011). Additional provisions
applicable to Form N-SAR filers are set forth in the EDGAR Filer
Manual, Volume III: ``N-SAR Supplement,'' Version 2 (August 2011). All
of these provisions have been incorporated by reference into the Code
of Federal Regulations, which action was approved by the Director of
the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR Part
51. You must comply with these requirements in order for documents to
be timely received and accepted. You can obtain paper copies of the
EDGAR Filer Manual from the following address: Public Reference Room,
U.S. Securities and Exchange Commission, 100 F Street NE., Room 1543,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Electronic copies are available on the Commission's Web
site. The address for the Filer Manual is http://www.sec.gov/info/edgar.shtml. You can also inspect the document at the National Archives
and Records Administration (NARA). For information on the availability
of this material at NARA, call<PHONE_NUMBER>, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.

    Dated: November 22, 2011.

    By the Commission.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2011-30591 Filed 11-28-11; 8:45 am]
BILLING CODE 8011-01-P